Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • Breakthrough Discoveries
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Nitin Jain Image

      Nitin Jain, M.D.

      Department of Leukemia, Division of Cancer Medicine

      About Dr. Nitin Jain

      Nitin Jain, M.D., is a Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed clinical fellowship in Leukemia at MD Anderson followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MD Anderson in July 2012. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Dr. Jain's research interests focus on new drug development for patients with leukemia, especially CLL and ALL. Since 2021, he has also served as Director, Leukemia CAR-T Program within the Department of Leukemia, MD Anderson. 

      Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, ponatinib in T-ALL, and off-the-self allogeneic CARTs in B-ALL. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, Lancet, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others. 

      He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO). He secured first rank at the national level in India in the medical school (AIIMS) entrance examination. He received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014 and 2016. He has served as faculty on American Society of Hematology CRTI workshop from 2017-2019. He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award. In 2021, he was appointed Director of the CAR T program for the Leukemia Department, MD Anderson. In 2022, he received Leukemia and Lymphoma Society (LLS) Scholar in Clinical Research award as well as LLS Translational Research Program (TRP) award.

      Read More

      Meet Nitin Jain, M.D.

      In the News

      ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias

      Illustration of a leukemia cell in the blood

      Can leukemia be treated with a pill?

      Present Title & Affiliation

      Primary Appointment

      Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2002All India Institute of Medical Sciences (AIIMS), New Delhi, IN, MBBS in Medicine

      Postgraduate Training

      2009-2012Clinical Fellowship, Hematology-Oncology, University of Chicago Medical Center, Chicago, Illinois
      2008-2009Clinical Fellowship, Leukemia, Memorial Sloan-Kettering Cancer Center, New York, New York
      2007-2008Clinical Fellowship, Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas
      2004-2007Clinical Residency, Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
      2003-2003House Officer, All India Institute of Medical Sciences (AIIMS), New Delhi
      2002-2002Clinical Internship, All India Institute of Medical Sciences (AIIMS), New Delhi

      Licenses & Certifications

      2012Medical Oncology
      2012Hematology
      2012Texas Medical License
      2007Internal Medicine

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2023

      Assistant Professor, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018

      Administrative Appointments/Responsibilities

      Vice Chair, Faculty Development and Wellness, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present

      Center Medical Director, Bone Marrow Aspiration Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present

      Director, Leukemia CAR-T Program, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present

      Extramural Institutional Committee Activities

      Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - 2025

      Co-Leader, CLL MoonShot, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2020 - 2026

      Member, CARTOX, The University of Texas MD Anderson Cancer Center, 2016 - Present

      Member, Scientific Research Committee (SRC), Member, The University of Texas MD Anderson Cancer Center, 2016 - 2018

      Associate Member, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2014 - 2016

      Editorial Activities

      Editorial Board Member, Cancer, 2020

      Editorial Board Member, Clinical Lymphoma Myeloma and Leukemia, 2017

      Editorial Board Member, Blood Advances, 2016 - 2020

      Series Editor, Chronic Lymphocytic Leukemia, Current Hematologic Malignancy Reports, 2015

      Co-Editor, @Point of Care (CLL), 2015

      Honors & Awards

      2022 - PresentLeukemia and Lymphoma Society (LLS) Translational Research Program (TRP) Award
      2022 - PresentLeukemia and Lymphoma Society (LLS) Scholar in Clinical Research
      2020Faculty Scholar Award, MD Anderson Cancer Center
      2018Sabin Family Foundation Fellow, MD Anderson Cancer Center
      2017Faculty, Clinical Research Training Institute (CRTI), American Society of Hematology
      2016Outstanding Young Investigator in Hematology, Indo-American Cancer Association
      2014High-Impact Clinical Research Support Program (HI-CRSP), MD Anderson Cancer Center
      2014Clinical Research Training Institute (CRTI), American Society of Hematology
      2008Merit Award, American Society of Clinical Oncology
      2006First Place Team, Doctors' Dilemma Medical Quiz Competition, American College of Physicians (Wisconsin Chapter)
      2002Ranked Second Overall in the Graduating Medical School Class, All India Institute of Medical Sciences
      1999Sardari Lal Kalra Gold Medal in Microbiology, All India Institute of Medical Sciences
      1998Scholarship for Academic Excellence, All India Institute of Medical Sciences
      1997First Rank in the country (India) for Medical School Entrance Examination, All India Institute of Medical Sciences
      1997National Merit Scholarship, Government of India

      Professional Memberships

      ASH CRTI Study Section

      2020 - 2020

      ASH CRTI Workshop

      2017 - 2019

      European Hematology Association

      2016 - Present

      Institutional Review Board, The University of Texas MD Anderson Cancer Center

      2014 - 2016

      American Society of Clinical Oncology

      2008 - Present

      American Society of Hematology

      2007 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2017. Treatment of Relapsed CLL. Conference. Treatment of Relapsed CLL. Houston, TX, US.
      2. 2017. Firstline treatment of CLL. Conference. Firstline treatment of CLL. Houston, TX, US.
      3. 2016. PI3 Kinase Inhibitors in CLL. Conference. PI3 Kinase Inhibitors in CLL. Houston, TX, US.
      4. 2015. Checkpoint Inhibitors in CLL. Conference. Checkpoint Inhibitors in CLL. Houston, TX, US.

      Regional Presentations

      1. 2018. CLL - Patient Education Program. Conference. CLL - Patient Education Program. San Antonio, TX, US.
      2. 2016. CLL - Patient Education Program. Conference. CLL - Patient Education Program. Omaha, NE, US.
      3. 2015. CLL - Patient Education Program. Conference. CLL - Patient Education Program. Omaha, NE, US.

      National Presentations

      1. 2019. ASH Updates in CLL. Conference. Banner MD Anderson. Phoenix, AZ, US.
      2. 2019. Official ASH Updates in CLL (North America). Conference. American Society of Hematology, US.
      3. 2018. Frontline therapy of CLL (Education Session). Conference. American Society of Hematology. San Diego, CA, US.
      4. 2018. Updates in Acute Lymphoblastic Leukemia. Conference. Updates in Acute Lymphoblastic Leukemia. Maui, HI, US.
      5. 2017. CLL State of the Art Update. Conference. CLL State of the Art Update. Houston, TX, US.
      6. 2017. Oral Abstract Discussion (CLL). Conference. Oral Abstract Discussion (CLL). Chicago, IL, US.
      7. 2017. Novel Combination Strategies in CLL. Conference. Novel Combination Strategies in CLL. Washington DC, DC, US.
      8. 2017. Relapsed/Refractory CLL and MRD. Conference. Physicians Education Resource. Miami, FL, US.
      9. 2017. Genomics and expression profile of ALL: Utility in guiding therapy. Conference. Oncology Meeting Innovations. Dallas, TX, US.
      10. 2016. ALL 2016. MDACC Experience: HCVAD and Beyond. Conference. Society for Adolescent and Young Adult Oncology (SAYAO). Irvine, CA, US.
      11. 2016. New Monoclonal And Checkpoint Inhibitors in CLL. Conference. New Monoclonal And Checkpoint Inhibitors in CLL. Houston, TX, US.
      12. 2016. Defining The Immune Checkpoint Landscape in Leukemias: Clinicopathologic Correlations. Conference. Defining The Immune Checkpoint Landscape in Leukemias: Clinicopathologic Correlations. Houston, TX, US.
      13. 2016. Advances and Treatments in Chronic Lymphocytic Leukemia (CLL). Conference. Medical Oncology and Hematology 2016. Houston, TX, US.
      14. 2015. Prevalence and Economic Burden of CLL in the Era of Oral Targeted Therapies. Conference. American Society of Hematology. Orlando, FL, US.
      15. 2015. Current Trends in treatment for B-cell. Conference. Auven Therapeutics. Philadelphia, PA, US.
      16. 2015. New immune therapy for CLL. Conference. CTRC, Health Science Center, San Antonio. San Antonio, TX, US.
      17. 2015. Targeted Therapy in CLL. Conference. University of Nebraska Medical Center. Omaha, NE, US.
      18. 2015. Checkpoint Inhibitors: Why Should They Work in CLL?. Conference. Checkpoint Inhibitors: Why Should They Work in CLL?. Houston, TX, US.
      19. 2014. PI3K Inhibition (Idelalisib) in CLL. Conference. Chemotherapy Foundation Symposium. New York, NY, US.
      20. 2014. Richter Syndrome: From Biology to Treatment. Conference. SOHO Annual Meeting. Houston, TX, US.

      International Presentations

      1. 2019. Official ASH Updates in CLL. Conference. American Society of Hematology. Lima, PE.
      2. 2019. Official ASH Updates in CLL (Mediterranean). Conference. American Society of Hematology. Athens, GR.
      3. 2019. ASH Updates in CLL. Conference. CCOLD Meeting. Banff, CA.
      4. 2019. ASH Updates in CLL. Conference. American Society of Hematology. New Delhi, IN.
      5. 2017. Immune Therapy of ALL. Conference. Immune Therapy of ALL. Guwahati, IN.
      6. 2017. CLL: State of the Art Update. Conference. CLL: State of the Art Update. Guwahati, IN.
      7. 2017. Making sense of Chronic Lymphocytic Leukemia management. Conference. Making sense of Chronic Lymphocytic Leukemia management. Abu Dhabi, AE.
      8. 2017. New Developments in Richter Syndrome (Hematology-in-focus session). Conference. New Developments in Richter Syndrome (Hematology-in-focus session). Madrid, ES.
      9. 2017. Immunotherapy in ALL. Conference. Pan Arab Hematology Congress. Kuwait, KW.
      10. 2017. ALL 2017. MDACC Experience: HCVAD and Beyond. Conference. Pan Arab Hematology Congress. Kuwait, KW.
      11. 2017. CLL 2017. Conference. Pan Arab Hematology Congress. Kuwait, KW.
      12. 2015. Prevalence and Economic Burden of CLL in the Era of Oral Targeted Therapies. Conference. IWCLL. Sydney, AU.
      13. 2014. CML - First line options. Conference. Apollo Cancer Conclave. Chennai, IN.
      14. 2014. Update on Chronic Lymphocytic Leukemia. Conference. Apollo Cancer Conclave. Chennai, IN.
      15. 2014. Therapeutic Advances in Chronic Lymphocytic Leukemia. Conference. MDACC and Delhi Cancer Institute. New Delhi, IN.
      16. 2013. New Agents in Chronic Lymphocytic Leukemia (CLL). Conference. Hematology Mexico Society. Mazatlan, MX.

      Formal Peers

      1. 2017. State of the Art CLL. Invited. New Delhi, IN.
      2. 2016. How we treat acute lymphoblastic leukemia 2016. Invited. New Delhi, IN.
      3. 2016. How we treat acute lymphoblastic leukemia 2016. Invited. Chandigarh, IN.
      4. 2016. ASH 2015 Update in CLL. Invited. Omaha, NE, US.
      5. 2016. Chronic Lymphocytic Leukemia: State of the Art in 2016 and Beyond. Invited. Dallas, TX, US.
      6. 2015. ASH 2014 Update in CLL. Invited. Omaha, NE, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - 2026
      Title:Integrated Multi-Omics Profiling of Measurable Residual Disease Reveals Molecular Drivers and Therapeutic Resistance in CLL
      Funding Source:CLL Global
      Role:PI
      Date: 2023 - Present
      Title:2022-0531: A phase 2, open-label, multicenter, basket study evaluating the safety and efficacy of Brexucabtagene autoleucel in adults with rare B-cell Malignancies (ZUMA-25)
      Funding Source:Kite Pharma, Inc
      Role:PI
      Date: 2022 - 2027
      Title:Combination Targeted Therapy in Chronic Lymphocytic Leukemia
      Funding Source:Leukemia & Lymphoma Society
      Role:PI
      Date: 2022 - 2027
      Title:Combination Targeted Therapy in Chronic Lymphocytic Leukemia
      Funding Source:Leukemia and Lymphoma Society
      Role:PI
      ID:2341-23
      Date: 2022 - 2025
      Title:LCK-targeted Therapy in T cell Acute Lymphoblastic Leukemia
      Funding Source:Leukemia and Lymphoma Society
      Role:PI
      ID:6665-23
      Date: 2022 - 2025
      Title:2021-0802 -- A Phase II Study of the Combination of Ponatinib with Mini-hyper CVD Chemotherapy and Venetoclax in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
      Funding Source:Leukemia & Lymphoma Society and Takeda
      Role:PI
      ID:00013912
      Date: 2021 - 2024
      Title:2021-0272 - A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
      Funding Source:MingSight Pharmaceuticals, Inc
      Role:PI
      Date: 2021 - 2024
      Title:2020-0571 -- Ipilimumab Combined with Ibrutinib and Nivolumab for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
      Funding Source:Bristol-Myers Squibb
      Role:PI
      Date: 2020 - 2028
      Title:2020-0775 -- A Phase I Study of FT819 in Subjects with B-cell Malignancies
      Funding Source:Fate Therapeutics, Inc
      Role:PI
      Date: 2020 - 2027
      Title:Protocol 2020-0411 -- Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-based therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma
      Funding Source:Aprea
      Role:PI
      Date: 2020 - 2027
      Title:Protocol 2019-0559 -- Long-term follow up of subjects who received PBCAR0191 in other clinical studies
      Funding Source:Precision BioSciences, Inc
      Role:PI
      Date: 2019 - 2026
      Title:2019-0218 -- A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
      Funding Source:Precision BioSciences
      Role:PI
      ID:2019-0218
      Date: 2019 - 2024
      Title:Targeting mitochondrial complex I in acute lymphoblastic leukemia
      Funding Source:NIH/NCI
      Role:Co-PI
      ID:R01CA231364 (Konopleva)
      Date: 2018 - 2022
      Title:Combined BTK and BCL2 Inhibition in CLL: A Non-Chemotherapy Therapeutic Approach
      Funding Source:Leukemia and Lymphoma Society
      Role:PI
      Date: 2018 - 2025
      Title:2017-1003: Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor) in patients with relapsed or refractory CD22+B-cell acute lyphoblastic leukemia (B-ALL)
      Funding Source:Cellectis
      Role:PI
      Date: 2018 - 2020
      Title:Combined BTK and BCL2 Inhibition in CLL: A Non-Chemotherapy Therapeutic Approach
      Funding Source:Andrew Sabin Family Foundation Fellows Award
      Role:PI
      Date: 2017 - 2023
      Title:2017-0938: A Phase 1/11 Study to Evaluate the Safety and Anti-tumor Activity of ADCT-602 targeting CD22 in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
      Funding Source:ADC Therapeutics
      Role:PI
      Date: 2017 - Present
      Title:2016-0727 -- Long-term follow-up study of patients who have previously been exposed to UCART19/ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
      Funding Source:I.R.I.S
      Role:PI
      Date: 2017 - 2021
      Title:Protocol 2016-0725 -- Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)
      Funding Source:I.R.I.S
      Role:PI
      Date: 2016 - 2026
      Title:2015-1097: Atezolizumab (PD-L1 mAb) in Combination with Obinutuzumab and Venetoclax for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
      Funding Source:Genentech, Inc
      Role:PI
      ID:4518
      Date: 2016 - Present
      Title:2015-0860: A Phase II Study of Venetoclax and Ibrutinib in Patients with
      Funding Source:Abbvie
      Role:PI
      Date: 2016 - 2021
      Title:Preclinical and Clinical Development of Isoform Specific PI3Kinase Inhibitor, IPI-145 (Duvelisib) in Chronic Lymphocytic Leukemia
      Funding Source:NIH/NCI
      Role:CO-I
      ID:15750 PA-13-302
      Date: 2016 - Present
      Title:2015-0281: First-line Therapy with Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV gene and Non-del(17p)
      Funding Source:Genentech, Inc
      Role:PI
      ID:51523
      Date: 2016 - Present
      Title:2015-0281: First-line Therapy with Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV gene and Non-del(17p)
      Funding Source:Pharmacyclics, Inc
      Role:PI
      ID:51524
      Date: 2015 - 2019
      Title:Targeting apoptosis in ALL with venetoclax and cytotoxic chemotherapy
      Funding Source:Leukemia and Lymphoma Society
      Role:CO-I
      ID:P-TRP-7089-15
      Date: 2015 - 2018
      Title:Immune Checkpoint Blockade in Chronic Lymphocytic Leukemia
      Funding Source:Leukemia and Lymphoma Society
      Role:PI
      ID:P-TRP-6599-15
      Date: 2015 - 2018
      Title:Dual targeting of MAPK and AKT pathways in Ras-mutated AML
      Funding Source:American Society of Clinical Oncology (ASCO)
      Role:PI
      ID:01
      Date: 2015 - 2017
      Title:Targeting Oncogenic RAS mutations in AML: Mechanisms of Therapeutic Response and Resistance
      Funding Source:NIH/NCI
      Role:CO-I
      ID:1 R21 CA187704-01A1
      Date: 2015 - 2018
      Title:2014-0794: A Phase 1b Study of IPI-145 Administered in Combination with Obinutuzumab in Patients with CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor (BTKi)
      Funding Source:Infinity Pharmaceuticals, Inc
      Role:PI
      ID:15224
      Date: 2015 - 2020
      Title:Defining and Treating Targetable Lesions in AYA Acute Lymphoblastic
      Funding Source:Cancer Prevention & Research Institute of Texas (CPRIT)
      Role:CO-I
      ID:RP150006
      Date: 2014 - 2019
      Title:2014-0931: Nivolumab in Combination with Ibrutinib in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL)
      Funding Source:Bristol Myers Squibb, Co
      Role:PI
      ID:39993
      Date: 2014 - 2017
      Title:2014-0932: Urelumab (CD137 mAb) Combined with Rituximab for Relapsed, Refractory or High-risk Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
      Funding Source:Bristol Myers Squibb, Co
      Role:PI
      ID:39996
      Date: 2014 - 2017
      Title:2014-0933: Lirilumab (anti-KIR mAb) Combined with Rituximab for Relapsed, Refractory or High-risk Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
      Funding Source:Bristol Myers Squibb Co
      Role:PI
      ID:39997
      Date: 2014 - 2020
      Title:2013-0479: An Open-Label Study of Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
      Funding Source:Pfizer
      Role:CO-I
      ID:8606
      Date: 2014 - 2019
      Title:2014-0435: Combination of Bosutinib and Inotuzumab Ozogamicin in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia Lymphoid Blast Crisis
      Funding Source:Pfizer
      Role:PI
      ID:12172
      Date: 2014 - 2017
      Title:Dual targeting of MAPK and AKT pathways in Ras-mutated AML
      Funding Source:American Society of Clinical Oncology (ASCO)
      Role:PI
      ID:01
      Date: 2014 - 2016
      Title:Targeting Oncogenic RAS mutations in AML: Mechanisms of Therapeutic Response and Resistance
      Funding Source:NIH/NCI
      Role:CO-I
      ID:1 R21 CA187704-01
      Date: 2014 - 2016
      Title:2013-0706: Brentuximab Vedotin in CD30-Positive Relapsed/Refractory Acute Myeloid Leukemia
      Funding Source:Seattle Genetics
      Role:PI
      ID:9513
      Date: 2014 - 2016
      Title:A Phase II Study of MEK 1/2 Inhibitor GSK212 (trametinib) in Combination with AKT Inhibitor GSK795 in Acute Myeloid Leukemia (AML) with Ras Mutations
      Funding Source:MDACC HI-CRSP
      Role:PI
      ID:01
      Date: 2013 - 2014
      Title:2013-0001: A Phase II Study of MEK 1/2 Inhibitor GSK212 (trametinib) in Combination with AKT Inhibitor GSK795 in Acute Myeloid Leukemia (AML) with Ras Mutations
      Funding Source:NIH/NCI
      Role:PI
      ID:CTEP
      Date: 2013 - 2017
      Title:2012-1040: A Phase I Study of IPI-145 in Patients with Advanced Hematologic Malignancie
      Funding Source:Infinity Pharmaceuticals, Inc
      Role:PI
      ID:40116
      Title:2015-0618: A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
      Funding Source:ADC Therapeutics
      Role:PI
      ID:ADCT402102
      Title:2015-0618: Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia
      Funding Source:ADC Therapeutics
      Role:PI
      ID:ADCT301002
      Title:A Phase II Study of the Combination of Ruxolitinib or Dasatinib with Chemotherapy in Patients with Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
      Funding Source:Incyte Corporation
      Role:PI
      ID:1
      Title:2021-0578: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients with Treatment-naïve Chronic Lymphocytic Leukemia (CLL)
      Funding Source:Loxo Oncology / Lilly USA, LLC
      Role:PI
      ID:RCTS 60837
      Title:2022-0806: A phase 1b study of oral AS-1763 in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma or non hodgkin lymphoma
      Funding Source:Carna Biosciences, Inc
      Role:PI
      Title:Personalized Medicine for Adult B-cell
      Funding Source:American Society of Hematology (ASH)
      Role:PI
      ID:1

      Selected Publications

      Peer-Reviewed Articles

      1. Khaire, N, Jabbour, EJ, Kadia, TM, Short, NJ, Borthakur, G, Pemmaraju, N, Daver, N, Maiti, A, Kebriaei, P, Paul, S, Garris, R, Ravandi-Kashani, F, Kantarjian, HM, Jain, N. Combination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL. Blood Neoplasia 3(4), 2026. e-Pub 2026. PMID: 42866674.
      2. Goulart H, Davids MS, Jain N. Chemotherapy-free regimens for Richter transformation: a bridge, but not yet a destination. Haematologica, 2026. e-Pub 2026. PMID: 42719966.
      3. Azevedo RS, Jabbour E, Jain N, Haddad FG, Kebriaei P, Khouri I, Shpall EJ, Champlin R, Karrar O, Maroun M, Senapati J, Kugler E, Garris RS, Ravandi F, Kantarjian H, Short NJ. Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage. Leukemia 40(9):2008-2017, 2026. e-Pub 2026. PMID: 42463941.
      4. Swaminathan M, Abbas HA, Roth M, Hildebrandt MAT, Fingrut W, Kadia T, Daver N, DiNardo C, Borthakur G, Jabbour E, Pemmaraju N, Alvarado Y, Ohanian M, Jain N, Short N, Bose P, Takahashi K, Pierce S, Hwang H, Huang X, Edelkamp P, Kebriaei P, Popat U, Shpall E, Garcia-Manero G, Ravandi F. Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 26(9):e1115-e1122.e14, 2026. e-Pub 2026. PMID: 42469064.
      5. Arora S, Senapati J, Chu V, Pemmaraju N, Bose P, Jabbour E, Kadia T, Ning J, Saenz D, Zhou L, Halim H, Alvarado Y, Ohanian M, DiNardo C, Takahashi K, Jain N, Ravandi F, Kantarjian H, Garcia-Manero G, Masarova L, Daver N. Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis. Haematologica, 2026. e-Pub 2026. PMID: 42657929.
      6. Kantarjian, HM, Jen, WY, Kugler, E, Garris, R, Pierce, S, Jain, N, Short, NJ, Khouri, IF, Loghavi, S, Haddad, FG, Ravandi-Kashani, F, Jabbour, EJ. Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 132(15), 2026. e-Pub 2026. PMID: 42482409.
      7. Jen, WY, Jabbour, EJ, Kugler, E, Jain, N, Garris, R, Short, NJ, Pierce, S, Khouri, IF, Wang, S, Haddad, FG, Ravandi-Kashani, F, Kantarjian, HM. Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 26(8):519-525, 2026. e-Pub 2026. PMID: 42392945.
      8. Keam S, Li YJ, Chu Y, Tayar JH, Lu H, Wu M, Agarwal SK, Jain N, Msaouel P, Diab A, Wang L, Haymaker C, Nurieva R, Kim ST. Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis. Cancer Immunol Res 14(10):1653-1669, 2026. e-Pub 2026. PMID: 42536056.
      9. Karulkar A, Jain H, Sidharthan N, Bhurani D, Melinkeri S, Boyella PK, Mehta P, Kaul E, Shah S, P K J, Nair C, Bhargava R, Bagal B, Nayak L, Shetty A, Menon H, Boya RR, Abhinav R, Kalra D, Ravikumar S, Thorat J, Purwar S, Shah NN, Fry T, Jain N, Neelapu S, Sengar M, Purwar R. Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety. Blood Cancer J, 2026. e-Pub 2026. PMID: 42463637.
      10. Lane AA, Luskin MR, Keating JH, LeBoeuf NR, Garcia JS, Shimony S, Leonard R, Goodpaster A, Nguyen T, Galinsky I, Eberly Puleo A, Daver NG, Jain N, Garcia-Manero G, Kantarjian HM, Konopleva M, Stein AS, Pemmaraju N. Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood, 2026. e-Pub 2026. PMID: 42413008.
      11. Htut TW, Kekedjian J, Short N, Bazinet A, Alvarado Y, Bataller A, Issa G, Borthakur G, Maiti A, Yilmaz M, Jain N, Masarova L, Chien K, Senapati J, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Garcia-Manero G, Ravandi F. Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia. Haematologica, 2026. e-Pub 2026. PMID: 42389833.
      12. Jabbour E, Rausch CR, Goulart H, Jain N, Ravandi F, Maiti A, Alvarado Y, Burger J, Yilmaz M, Khouri I, Kebriaei P, Jorgensen J, Wang SA, Wang X, Mayor E, Garris RS, Short NJ, Kantarjian H. Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. Blood Cancer J 16(1), 2026. e-Pub 2026. PMID: 42365008.
      13. Miatech J, Milton DR, Gaballa MR, Banerjee P, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Al-Atrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi-Kashani F, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Haematologica, 2026. e-Pub 2026. PMID: 42237781.
      14. Jamison T, Jabbour E, Karrar O, Jain N, Haddad FG, Kebriaei P, Khouri I, Popat U, Yang H, Kugler E, Garris R, Garcia-Manero G, Kantarjian H, Short NJ. Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring. Leuk Lymphoma:1-4, 2026. e-Pub 2026. PMID: 42220306.
      15. Goulart H, Short NJ, Borthakur G, Jain N, DiNardo C, Loghavi S, Khouri R, Hachem M, Ravandi F, Daver N, Kadia TM, Yilmaz M, Issa G, Bazinet A, Swaminathan M, Montalban-Bravo G, Haddad F, Garris R, Kantarjian H, Jabbour E. Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia. Blood Adv 10(9):3276-3280, 2026. e-Pub 2026. PMID: 41860396.
      16. Timofeeva N, Herrera B, Fujiwara H, Asami T, Endo H, Hatakeyama M, Nakajima F, Ohmoto H, Nishioka Y, Miyamoto K, Arimura A, Tantawy SI, Pinilla-Ibarz J, Coombs CC, Jain N, Sawa M, Gandhi V. Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. Blood Cancer J 16(1), 2026. e-Pub 2026. PMID: 42098067.
      17. Tang, G, Reynolds, A, Ravandi-Kashani, F, Medeiros, LJ, Kornblau, SM, Jabbour, EJ, Jain, N, Short, NJ, Hu, S, Wei, Q, Loghavi, S, Ok, CY, Toruner, GA, Ling, J, Liang, S, Verma, T, Zou, Y, Wang, S. Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia Using Optical Genome Mapping, Karyotyping, and Next-Generation Sequencing. Modern Pathology 39(5), 2026. e-Pub 2026. PMID: 41796805.
      18. Tang, G, Wang, SA, Jen, WY, Medeiros, LJ, Wang, W, Fang, H, Hu, S, Jain, N, Jabbour, EJ, Zou, Y, Xu, J. Acute leukemia with BCL11B rearrangements. Human Pathology 171, 2026. e-Pub 2026. PMID: 41581705.
      19. Swaminathan M, Ferrajoli A, Thompson PA, Burger J, Borthakur G, Takahashi K, Estrov Z, Bharathi V, Bataller A, Kadia TM, Pemmaraju N, Daver N, Jabbour E, Bose P, Kanagal-Shamanna R, Patel KP, Wang SA, Garg N, Hwang H, Wang X, Qiao W, Xu X, Cruz N, Ayala A, Pierce S, Plunkett W, Sampath D, Kantarjian HM, Keating MJ, Gandhi V, Wierda WG, Jain N. Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Blood Cancer Discov 7(3):432-440, 2026. e-Pub 2026. PMID: 41678768.
      20. Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, DiNardo C, Jabbour E, Rausch CR, Issa GC, Pemmaraju N, Ohanian M, Maiti A, Montalban-Bravo G, Sasaki K, Bouligny IM, Yilmaz M, Haddad FG, Masarova L, Chien K, Alvarado Y, Jain N, Popat U, Shpall E, Loghavi S, Qiao W, Wang X, Garcia-Manero G, Ravandi F, Kantarjian HM. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 101(7):1737-1747, 2026. e-Pub 2026. PMID: 42035228.
      21. Kantarjian, HM, Qiao, W, Jain, N, Jen, WY, Kugler, E, Short, NJ, Garris, R, Pierce, S, Kebriaei, P, Wang, SA, Haddad, FG, Ravandi-Kashani, F, Huang, X, Jabbour, EJ. Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia. Cancer 132(8), 2026. e-Pub 2026. PMID: 41954167.
      22. Goulart H, Braish J, Short NJ, Jain N, Sasaki K, Kantarjian H, Jabbour EJ. A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia Positive Acute Lymphoblastic Leukemia. Acta Haematol:1-8, 2026. e-Pub 2026. PMID: 41915597.
      23. Furman RR, Wierda WG, Patten PE, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM MD, Byrd JC. Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Blood Adv 10(11):3931-3941, 2026. e-Pub 2026. PMID: 41915892.
      24. Nguyen D, Jabbour E, Kantarjian HM, Macaron W, Jain N, Nasnas C, Kebriaei P, Shpall EJ, Khouri I, Haddad F, Karrar O, Maroun M, Garris R, Ravandi F, Short NJ. Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia. Haematologica, 2026. e-Pub 2026. PMID: 41885010.
      25. Bazinet A, Ferrajoli A, Jain N, Burger JA, Yilmaz M, Swaminathan M, Kantarjian HM, Keating M, Thompson PA, Wierda WG. NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy. Blood Adv 10(12):4113-4116, 2026. e-Pub 2026. PMID: 41879712.
      26. Singh A, Daver N, Loghavi S, Kadia T, Ravandi F, DiNardo C, Borthakur G, Pierce S, Futreal A, Aung PP, Cuglievan B, Jain N, Jabbour E, Garcia-Manero G, Konopleva M, Qazilbash M, Pemmaraju N. Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma:1-4, 2026. e-Pub 2026. PMID: 41711093.
      27. DiNardo, C, Croden, J, Abdel-Salam, HM, Kadia, TM, Molica, M, Bazinet, A, Bose, P, Maiti, A, Haddad, FG, Burger, JA, Kantarjian, HM, Wierda, WG, Jain, N, Ferrajoli, A. Clinical, genetic, and familial features of POT1 tumor predisposition syndrome. Cancer 132(4), 2026. e-Pub 2026. PMID: 41686515.
      28. Azevedo, RS, Jabbour, EJ, Kantarjian, HM, Lavu, S, Loghavi, S, Jain, N, Sasaki, K, Garris, R, Takahashi, K, Ravandi-Kashani, F, Short, NJ. Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia. Blood 147(5):547-556, 2026. e-Pub 2026. PMID: 41335402.
      29. Short, NJ, Kantarjian, HM, Jain, N, Kadia, TM, Senapati, J, Haddad, FG, Maroun, MM, Sasaki, K, Xiao, L, Huang, X, Karrar, OS, Abramova, R, Zhao, M, Garris, R, Konopleva, M, Ravandi-Kashani, F, Jabbour, EJ. Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia. Blood Advances 10(1):25-28, 2026. e-Pub 2026. PMID: 40763277.
      30. Gordon, B, Muhowski, E, Singh, J, Ravikrishnan, J, Peris Cuesta, A, Diaz-Rohena, DY, Sanchez, JR, Thangavadivel, S, Benrashid, S, He, A, Marr, AR, Mitchell, A, Urrutia, JM, Misra, S, Lai, TH, Yu, L, Walker, B, Perry, E, Shukla, SA, Grieselhuber, NR, Rogers, KA, Lapalombella, R, Blachly, JS, Kittai, AS, Bhat, S, Jain, N, Wierda, WG, Byrd, JC, Niesman, M, Zhang, K, Sampath, D, Woyach, JA. PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia. Blood Cancer Discovery 7(1):85-103, 2026. e-Pub 2026. PMID: 41190953.
      31. Sabitha, P, Goel, A, Kumar, S, R, C, Fernandes, S, Jain, N, Pemmaraju, N, Sharma, A, Sahoo, RK. Blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 25, 2026. e-Pub 2026. PMID: 41890270.
      32. Sanchez, JR, Liu, C, Pawar, V, Huang, Y, Diaz-Rohena, DY, Singh, J, Koppikar, P, Lai, TH, St John, L, Puduvalli, VK, Molldrem, JJ, Thandapani, P, Jain, N, Lapalombella, R, Sampath, D. NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia. Leukemia and Lymphoma 67(1):97-107, 2026. e-Pub 2026. PMID: 41401031.
      33. Braish, J, Kantarjian, HM, Short, NJ, Tang, G, Daver, N, Kadia, TM, Senapati, J, Jen, WY, Takahashi, K, Garris, R, Garcia-Manero, G, Ravandi-Kashani, F, Jabbour, EJ, Jain, N. Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class Rearrangements. Clinical Lymphoma, Myeloma and Leukemia 26(1):e110-e113.e1, 2026. e-Pub 2026. PMID: 41125471.
      34. Pasvolsky, O, Shimony, S, Saliba, RM, Marcoux, C, Ledesma, C, Rondon, G, Tewari, P, Ragoonanan, D, Short, NJ, Jabbour, EJ, Gooptu, M, Ho, VT, Soiffer, RJ, Antin, JH, Koreth, J, Cutler, C, Paolino, JD, Duncan, C, Lehmann, L, DeAngelo, DJ, Jain, N, Champlin, RE, Shpall, E, Luskin, MR, Kebriaei, P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia—A Retrospective, Dual-Center Study. American journal of hematology 101(1):16-25, 2026. e-Pub 2026. PMID: 41051170.
      35. Bharathi V, Jen WY, Venugopal S, Thakral B, Daver N, Chien K, Bose P, Masarova L, Pemmaraju N, Tang G, Jain N. Durable complete remission with imatinib monotherapy in a patient with FIP1L1-PDGFRA rearranged myeloid neoplasm with extramedullary involvement. Leuk Lymphoma 67(1):225-228, 2026. e-Pub 2026. PMID: 41194520.
      36. Short, NJ, Kantarjian, HM, Furudate, K, Jain, N, Ravandi-Kashani, F, Karrar, OS, Loghavi, S, Nasr, L, Haddad, FG, Senapati, J, Garris, R, Takahashi, K, Jabbour, EJ. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 40369607.
      37. Goulart, H, Ravandi-Kashani, F, Short, NJ, Jain, N, Daver, N, Kadia, TM, DiNardo, C, Borthakur, G, Takahashi, K, Pemmaraju, N, Haddad, FG, Montalban Bravo, G, Alvarado, Y, Issa, GC, Bataller Torralba, A, Pierce, S, Loghavi, S, Tang, G, Wang, S, Thakral, B, Shpall, E, Champlin, RE, Khouri, IF, Kebriaei, P, Garcia-Manero, G, Sasaki, K, Jabbour, EJ, Senapati, J. Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41370732.
      38. Short, NJ, Jabbour, EJ, Macaron, W, Jain, N, Haddad, FG, Loghavi, S, Kadia, TM, Kebriaei, P, Kugler, E, Matthews, JA, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 41120271.
      39. Suryavanshi M, Mehta P, Jain N, Bhurani D, Boya RR, Mishra PC, Kumar D, Dhandha S, Kumar M, Das N, Mishra S. Validation of an Adapted NGS-Based Clonality Assay for MRD Monitoring in B-ALL Using Archived and Follow-Up Samples. EJHaem 6(6):e70202, 2025. e-Pub 2025. PMID: 41425693.
      40. Arani N, Rausch CR, Geppner A, Borthakur G, Jain N, Ferrajoli A, Jabbour E, Sampath D, Hosing C, Vega F, Kantarjian HM, Kadia TM. Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia. Leuk Lymphoma 66(14):2794-2798, 2025. e-Pub 2025. PMID: 41124080.
      41. Goulart, H, Jabbour, EJ, Short, NJ, Kadia, TM, Pemmaraju, N, Takahashi, K, Ravandi-Kashani, F, Konopleva, M, Jain, N. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 25(11):800-807, 2025. e-Pub 2025. PMID: 40500616.
      42. Nirmalanantham, P, Quesada, AE, Ghosh, A, Lin, P, Ok, CY, Yang, RK, Fang, H, Garces, S, Kanagal Shamanna, R, Loghavi, S, Routbort, MJ, Yin, CC, Wei, W, Pasyar, S, Bassett Jr, R, El Hussein, S, Jain, N, Burger, JA, Wierda, WG, Wang, S, Bueso-Ramos, CE, Patel, KP, Medeiros, LJ, Jelloul, FZ. Mutational Landscape and Clinical Impact of SPEN Mutations in Patients with Chronic Lymphocytic Leukemia. Cancers 17(21), 2025. e-Pub 2025. PMID: 41228377.
      43. Uyanik MS, Jabbour E, Short N, Sasaki K, Paul S, Garcia-Manero G, Kadia T, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients. Leuk Lymphoma 66(11):2132-2134, 2025. e-Pub 2025. PMID: 40618389.
      44. Habib, D, Jabbour, EJ, Bataller Torralba, A, Sasaki, K, Tang, G, Loghavi, S, Li, S, Senapati, J, Short, NJ, Jain, N, Kantarjian, HM, Haddad, FG. Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18). Clinical Lymphoma, Myeloma and Leukemia 25(9):672-675, 2025. e-Pub 2025. PMID: 40222876.
      45. Hill JW, Marvin-Peek J, Sasaki K, Bresser S, Dabaja BS, Jain N, Borthakur G, Abbas HA. Central nervous system relapse of core-binding factor acute myeloid leukemia. Leuk Lymphoma 66(9):1745-1748, 2025. e-Pub 2025. PMID: 40386862.
      46. Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
      47. Berkman, AM, Andersen, C, Puthenpura, V, Short, NJ, Merriman, K, Swaminathan, M, Cuglievan, B, McCall, DC, DiNardo, C, Nunez, CA, Jain, N, Kadia, TM, Issa, GC, Gibson, A, Garcia, MB, Andrew Livingston, J, Parsons, SK, Hildebrandt, MA, Roth, M. Risk of early death after acute leukemia diagnosis among adolescents and young adults. JNCI Cancer Spectrum 9(4), 2025. e-Pub 2025. PMID: 40579211.
      48. Kharfan-Dabaja, MA, Kumar, A, Pinilla-Ibarz, J, Brown, JR, Shadman, M, Awan, FT, Kenderian, S, Siddiqi, T, Abramson, JS, Al-Juhaishi, T, Brander, D, Coombs, CC, Furman, RR, Jain, N, Khan, N, Saba, N, Collins, JM, Beitinjaneh, AM, Stephens, DM, Woyach, JA, Hamadani, M. Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy 31(8):494-504, 2025. e-Pub 2025. PMID: 40514010.
      49. Jain N, Eyre TA, Winfree KB, Bhandari NR, Khanal M, Sugihara T, Chen Y, Abada P, Patel K. Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 66(8):1400-1412, 2025. e-Pub 2025. PMID: 40122053.
      50. Chien, KS, Curry, JL, Pemmaraju, N, Jain, N. Leukemia Cutis in the Setting of Indolent Chronic Lymphocytic Leukemia. American journal of hematology 100(7):1240-1241, 2025. e-Pub 2025. PMID: 40062658.
      51. Uryu, H, Saeki, K, Haeno, H, Kapadia, C, Furudate, D.M.D., Ph.D., K, Nangalia, J, Spencer Chapman, M, Zhao, L, Hsu, JI, Zhao, C, Chen, S, Tanaka, T, Li, Z, Ogata, S, Hanache, S, Yang, H, DiNardo, C, Daver, N, Pemmaraju, N, Jain, N, Ravandi-Kashani, F, Zhang, J, Song, X, Thompson, EJ, Tang, H, Little, L, Gumbs, C, Orlowski, R, Qazilbash, MH, Bhalla, K, Colla, S, Kantarjian, HM, Kanagal Shamanna, R, Bueso-Ramos, CE, Nakada, D, Al-Atrash, G, Molldrem, JJ, Futreal, A, Shpall, E, Goodell, MA, Garcia-Manero, G, Takahashi, K. Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. Nature Genetics 57(7):1695-1707, 2025. e-Pub 2025. PMID: 40596442.
      52. Senapati, J, Loghavi, S, Marvin-Peek, J, Garcia-Manero, G, Kadia, TM, Borthakur, G, Daver, N, Short, NJ, Jain, N, Issa, GC, Haddad, FG, Hammond, D, Chien, KS, Tang, G, Thakral, B, Montalban Bravo, G, Pemmaraju, N, Bazinet, A, Swaminathan, M, Pierce, S, Abbas, HA, Reville, PK, Popat, UR, Shpall, EJ, Champlin, RE, Jabbour, EJ, Ravandi-Kashani, F, Kantarjian, HM, DiNardo, C. Clinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia. American journal of hematology 100(5):758-769, 2025. e-Pub 2025. PMID: 39921561.
      53. Sasaki, K, Garcia-Manero, G, Nigo, M, Jabbour, EJ, Ravandi-Kashani, F, Wierda, WG, Jain, N, Takahashi, K, Montalban Bravo, G, Daver, N, Thompson, PA, Pemmaraju, N, Kontoyiannis, DP, Sato, J, Karimaghaei, S, Soltysiak, KA, Raad, II, Kantarjian, HM, Carter, B. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clinical Lymphoma, Myeloma and Leukemia 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
      54. Goulart, H, Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer 131(8), 2025. e-Pub 2025. PMID: 40193193.
      55. Goulart, H, Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer 131(8), 2025. e-Pub 2025. PMID: 40193193.
      56. DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
      57. Jain, H, Karulkar, A, Kalra, D, Ravikumar, S, Shah, S, Firfiray, A, Pendhari, J, Jaiswal, AK, Khan, A, Sundharam, M, Vaibhaw, A, Saroha, A, Rajyopadhye, S, Basu, M, Asija, S, Chowdhury, A, Beher, R, Banik, A, Dwivedi, A, Purwar, S, Narula, G, Banavali, SD, Jain, N, Highfill, SL, Stroncek, DF, Fry, TJ, Melinkeri, S, Wilson, L, Agarwal, N, Aribandi, A, Boyella, PK, Shah, N, Neelapu, SS, Sengar, M, Purwar, R. Talicabtagene autoleucel for relapsed or refractory B-cell malignancies. The Lancet Haematology 12(4):e282-e293, 2025. e-Pub 2025. PMID: 40090352.
      58. Kantarjian, HM, Short, NJ, Jain, N, Haddad, FG, Kadia, TM, Yilmaz, M, Ferrajoli, A, Sasaki, K, Alvarado, Y, Pemmaraju, N, Senapati, J, Garris, R, Ravandi-Kashani, F, Jabbour, EJ. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American journal of hematology 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
      59. Kugler, E, Kantarjian, H, Jabbour, EJ, Khaire, N, Short, NJ, Kadia, TM, Haddad, FG, Sasaki, K, Kanagal Shamanna, R, Garris, R, Ravandi-Kashani, F, Jain, N. Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 131(5), 2025. e-Pub 2025. PMID: 39980368.
      60. Marvin-Peek, J, Shelton, V, Brassil, KJ, Fellman, B, Barr, A, Chien, KS, Hammond, DE, Swaminathan, M, Jain, N, Wierda, WG, Ferrajoli, A, DiNardo, C. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia. Acta haematologica 148(2):233-243, 2025. e-Pub 2025. PMID: 38861934.
      61. Kannan, S, Li, Y, Baran, N, Yang, X, Ghotbaldini, S, Tatarata, QZ, Yoshimura, S, Li, Z, Hsiao, YC, Balachander, S, Andersen, C, Cidado, J, Yu, J, Jain, N, Yang, JJ, Konopleva, M. Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Advances 9(3):473-487, 2025. e-Pub 2025. PMID: 39561378.
      62. Luskin, MR, Shimony, S, Keating, J, Winer, ES, Garcia, JS, Stone, RM, Jabbour, EJ, Flamand, Y, Stevenson, KE, Ryan, J, Zeng, Z, Letai, AG, Konopleva, M, Jain, N, DeAngelo, DJ. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Advances 9(3):617-626, 2025. e-Pub 2025. PMID: 39546748.
      63. Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
      64. Ravikrishnan, J, Diaz-Rohena, DY, Muhowski, E, Mo, X, Lai, TH, Misra, S, Williams, CD, Sanchez, JR, Mitchell, A, Satpati, S, Perry, E, Kaufman, T, Liu, C, Lozanski, A, Lozanski, G, Rogers, KA, Kittai, AS, Bhat, S, Collins, M, Davids, MS, Jain, N, Wierda, WG, Lapalombella, R, Byrd, JC, Tan, F, Chen, Y, Chen, Y, Shen, Y, Anthony, SP, Woyach, JA, Sampath, D. LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia. Haematologica 110(1):78-91, 2025. e-Pub 2025. PMID: 39113656.
      65. Kantarjian, H, Short, NJ, Haddad, FG, Jain, N, Huang, X, Montalban-Bravo, G, Kanagal-Shamanna, R, Kadia, TM, Daver, N, Chien, KS, Alvarado, Y, Garcia-Manero, G, Issa, GC, Garris, R, Nasnas, C, Nasr, L, Ravandi, F, Jabbour, EJ. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of Clinical Oncology 42(36):4246-4251, 2024. e-Pub 2024. PMID: 39028925.
      66. Kim, E, Chen, SS, Campbell, M, Hwang, H, Huang, X, Ferrajoli, A, Jain, N, Wierda, WG, Wodarz, D, Chiorazzi, N, Burger, JA. Deuterated water labeling in ibrutinib-treated patients with CLL. Blood 144(25):2678-2681, 2024. e-Pub 2024. PMID: 39441901.
      67. Abdel Rahman, Z, Othman, T, Saliba, RM, Vanegas, YM, Mohty, R, Ledesma, C, Rondon, G, Jain, N, Jabbour, EJ, Pullarkat, V, Alkhateeb, HB, Kantarjian, HM, Greipp, PT, Nakamura, R, Kharfan-Dabaja, MA, Champlin, RE, Forman, SJ, Shpall, E, Litzow, M, Foran, J, Aldoss, I, Koller, PB, Kebriaei, P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplantation and Cellular Therapy 30(12):1197-1205, 2024. e-Pub 2024. PMID: 39332807.
      68. Kismali, G, Manyam, GC, Jain, N, Ivan, C, Lamothe, B, Ayres, M, Iles, LR, Wierda, WG, Gandhi, VV. Transcriptomic clustering of chronic lymphocytic leukemia. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39695112.
      69. Zhang, R, Khare, P, Banerjee, P, Ivan, C, Schneider, S, Barbaglio, F, Dwyer, KC, Jensen, VB, Thompson, EJ, Mendoza, M, Chiorazzi, N, Chen, SS, Yan, XJ, Jain, N, Ghia, P, Caligaris-Cappio, F, Mendonsa, R, Kasimsetty, S, Swoboda, R, Bayraktar, R, Wierda, WG, Gandhi, VV, Calin, GA, Keating, M, Bertilaccio, MS. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39438453.
      70. Braish, J, Kugler, E, Jabbour, EJ, Woodman, K, Ravandi-Kashani, F, Nicholas, S, Jain, N, Kantarjian, HM, Sasaki, K. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(11):783-788, 2024. e-Pub 2024. PMID: 39013740.
      71. Braish, J, Kugler, E, Jabbour, EJ, Woodman, K, Ravandi-Kashani, F, Nicholas, S, Jain, N, Kantarjian, HM, Sasaki, K. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(11):783-788, 2024. e-Pub 2024. PMID: 39013740.
      72. Phan, L, Jabbour, EJ, Antonoff, MB, Jain, N, Lin, P, Moran, C, Pemmaraju, N. Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic Leukemia. Journal of Immunotherapy and Precision Oncology 7(4):314-316, 2024. e-Pub 2024. PMID: 39524462.
      73. Yoshimura, S, Li, Z, Gocho, Y, Yang, W, Crews, KR, Lee, SH, Roberts, KG, Mullighan, CG, Relling, M, Yu, J, Yeoh, AJ, Loh, ML, Saygin, C, Litzow, M, Jeha, S, Karol, S, Inaba, H, Pui, CH, Konopleva, M, Jain, N, Stock, W, Paietta, E, Jabbour, EJ, Kornblau, SM, Evans, W, Yang, JJ. Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 42(29):3478-3490, 2024. e-Pub 2024. PMID: 39102629.
      74. Ali, MA, Aiman, W, Kantarjian, HM, Jabbour, EJ, Ravandi-Kashani, F, Jain, N, Short, NJ, Sasaki, K. Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(10):e376-e384, 2024. e-Pub 2024. PMID: 38972767.
      75. Shah, BD, Mattison, R, Abboud, R, Abdelmessieh, P, Aldoss, I, Burke, PW, DeAngelo, DJ, Dinner, S, Fathi, AT, Gauthier, J, Haddadin, M, Jain, N, Jonas, BA, Kirby, S, Liedtke, M, Litzow, M, Logan, AC, Long, M, Luger, SM, Mangan, JK, Massaro, S, Stratford May, W, Oluwole, OO, Park, JH, Przespolewski, A, Rangaraju, S, Saygin, C, Schwartz, M, Shami, PJ, Tomlinson, B, Webster, JA, Awotiwon, A, Stehman, K. Acute Lymphoblastic Leukemia, Version 2.2024. JNCCN Journal of the National Comprehensive Cancer Network 22(8):563-576, 2024. e-Pub 2024. PMID: 39413812.
      76. Gibson A, Nunez C, Robusto L, Kammerer B, Garcia M, Roth M, Sheth R, Tewari P, Hittle A, Toepfer L, Torres R, Short NJ, Jabbour E, Jain N, Cuglievan B, McCall D. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica 109(9):3042-3047, 2024. e-Pub 2024. PMID: 38779719.
      77. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109(8):2660-2664, 2024. e-Pub 2024. PMID: 38572554.
      78. Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood 144(1):61-73, 2024. e-Pub 2024. PMID: 38551807.
      79. Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol 99(7):1423-1426, 2024. e-Pub 2024. PMID: 38607091.
      80. Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol 42(17):JCO2400033, 2024. e-Pub 2024. PMID: 38552193.
      81. Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
      82. Uryu H, Saeki K, Haeno H, Kapadia CD, Furudate K, Nangalia J, Chapman MS, Zhao L, Hsu JI, Zhao C, Chen S, Tanaka T, Li Z, Yang H, DiNardo C, Daver N, Pemmaraju N, Jain N, Ravandi F, Zhang J, Song X, Thompson E, Tang H, Little L, Gumbs C, Orlowski RZ, Qazilbash M, Bhalla K, Colla S, Kantarjian H, Shamanna RK, Ramos CB, Nakada D, Futreal PA, Shpall E, Goodell M, Garcia-Manero G, Takahashi K. Clonal evolution of hematopoietic stem cells after cancer chemotherapy. bioRxiv, 2024. e-Pub 2024. PMID: 38826462.
      83. Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
      84. Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell 42(4):552-567.e6, 2024. e-Pub 2024. PMID: 38593781.
      85. Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(4):e168-e173, 2024. e-Pub 2024. PMID: 38212207.
      86. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
      87. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. e-Pub 2024. PMID: 38537065.
      88. Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417-421, 2024. e-Pub 2024. PMID: 37879077.
      89. Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
      90. Jain N, Croner LJ, Allan JN, Siddiqi T, Tedeschi A, Badoux XC, Eckert K, Cheung LWK, Mukherjee A, Dean JP, Szafer-Glusman E, Seymour JF. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res 30(3):498-505, 2024. e-Pub 2024. PMID: 37955424.
      91. Tian Z, Shi C, Yang G, Allen JK, Shi Q, Al-Shami A, Olson JW, Smith MG, Chang Q, Kaur J, You J, Lofton TE, Gonzalez MA, Zhang Q, Zha D, Tasian SK, Jain N, Konopleva MY, Heffernan T, Molldrem JJ. Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia 38(1):226, 2024. e-Pub 2024. PMID: 38036631.
      92. Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv, 2023. e-Pub 2023. PMID: 38106221.
      93. Sasaki, K, Haddad, FG, Short, NJ, Jain, N, Issa, GC, Jabbour, EJ, Kantarjian, HM. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019. Cancer 129(23):3805-3814, 2023. e-Pub 2023. PMID: 37769040.
      94. Short, NJ, Muftuoglu, M, Ong, F, Nasr, L, Macaron, W, Montalban Bravo, G, Alvarado, Y, Basyal, M, Daver, N, DiNardo, C, Borthakur, G, Jain, N, Ohanian, M, Jabbour, EJ, Issa, GC, Qiao, W, Huang, X, Kanagal Shamanna, R, Patel, KP, Bose, P, Ravandi-Kashani, F, Delumpa, R, Abramova, R, Garcia-Manero, G, Andreeff, M, Cortes, JE, Kantarjian, HM. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. Journal of Hematology and Oncology 16(1), 2023. e-Pub 2023. PMID: 37422688.
      95. Senapati, J, Fiskus, WC, Daver, N, Wilson, NR, Ravandi-Kashani, F, Garcia-Manero, G, Kadia, TM, DiNardo, C, Jabbour, EJ, Burger, JA, Short, NJ, Alvarado, Y, Jain, N, Masarova, L, Issa, GC, Qiao, W, Khoury, J, Pierce, SR, Miller, D, Sasaki, K, Konopleva, M, Bhalla, K, Borthakur, G, Pemmaraju, N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clinical Cancer Research 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
      96. Kadia, TM, Ravandi-Kashani, F, Molica, M, Bataller, A, Borthakur, G, Daver, N, Jabbour, EJ, DiNardo, C, Pemmaraju, N, Jain, N, Ferrajoli, A, Ylimaz, M, Bose, P, Tidwell, R, Marx, KR, Rausch, CR, Kanagal Shamanna, R, Wang, S, Islam, R, Champlin, RE, Shpall, E, Konopleva, M, Garcia-Manero, G, Kantarjian, HM. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. American journal of hematology 98(11):1711-1720, 2023. e-Pub 2023. PMID: 37635400.
      97. Parry, EM, Lemvigh, C, Deng, S, Dangle, N, Ruthen, NG, Knisbacher, BA, Broséus, J, Hergalant, S, Guièze, R, Li, S, Zhang, W, Johnson, C, Long, JM, Yin, S, Werner, L, Anandappa, AJ, Purroy, N, Gohil, SH, Oliveira, G, Bachireddy, P, Shukla, SA, Huang, T, Khoury, J, Thakral, B, Dickinson, M, Tam, C, Livak, KJ, Getz, G, Neuberg, D, Feugier, P, Kharchenko, PV, Wierda, WG, Olsen, LR, Jain, N, Wu, C. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer cell 41(10):1803-1816.e8, 2023. e-Pub 2023. PMID: 37738974.
      98. Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626-2638, 2023. e-Pub 2023. PMID: 37078252.
      99. Haddad, FG, Sasaki, K, Bidikian, A, Issa, GC, Kadia, TM, Jain, N, Alvarado, Y, Short, NJ, Pemmaraju, N, Loghavi, S, Patel, KP, Kanagal Shamanna, R, Yilmaz, M, Masarova, L, Jabbour, EJ, Kantarjian, HM. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. American journal of hematology 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
      100. Tian, Z, Shi, C, Yang, G, Allen, J, Shi, Q, AI-Shami, A, Olson, JW, Smith, M, Chang, Q, Kaur, J, You, J, Lofton, T, Gonzalez, MA, Zhang, Q, Zha, D, Tasian, SK, Jain, N, Konopleva, M, Heffernan, TP, Molldrem, JJ. Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL. Leukemia 37(10):2006-2016, 2023. e-Pub 2023. PMID: 37634013.
      101. Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma 64(9):1554-1561, 2023. e-Pub 2023. PMID: 37317991.
      102. Short, NJ, Jabbour, EJ, Macaron, W, Ravandi-Kashani, F, Jain, N, Kanagal Shamanna, R, Patel, KP, Loghavi, S, Haddad, FG, Yilmaz, M, Issa, GC, Kebriaei, P, Kornblau, SM, Pelletier, S, Flores, W, Matthews, JA, Garris, R, Kantarjian, HM. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. American journal of hematology 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
      103. Pasvolsky O, Kebriaei P, Shah BD, Jabbour EJ, Jain N. Chimeric Antigen Receptor T Therapy for Adult B-Cell Acute Lymphoblastic Leukemia: State-of the-(C)ART and Road Ahead. Blood Adv 7(14):3350-3360, 2023. e-Pub 2023. PMID: 36912764.
      104. Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. e-Pub 2023. PMID: 37016930.
      105. Thompson, PA, Keating, M, Ferrajoli, A, Jain, N, Peterson, CB, Garg, N, Wang, SA, Jorgensen, JL, Kadia, TM, Bose, P, Pemmaraju, N, Short, NJ, Wierda, WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
      106. Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, Jain N, Garcia JS, Wong GC, Ooi M, Letai A, Konopleva M, Bhatt S. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv 7(12):2917-2923, 2023. e-Pub 2023. PMID: 36763538.
      107. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
      108. Desikan SP, Senapati J, Jabbour E, Abuasab T, Short N, Tang G, Wang S, Kebriaei P, Kadia T, Borthakur G, Ravandi F, Roberts K, Mullighan C, Konopleva M, Kantarjian H, Jain N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. Am J Hematol 98(6):E142-E144, 2023. e-Pub 2023. PMID: 36877196.
      109. Yoshimura S, Panetta JC, Hu J, Li L, Gocho Y, Du G, Umezawa A, Karol SE, Pui CH, Mullighan CG, Konopleva M, Stock W, Teachey DT, Jain N, Yang JJ. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 37(6):1194-1203, 2023. e-Pub 2023. PMID: 37076694.
      110. El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch 482(6):1011-1019, 2023. e-Pub 2023. PMID: 36864257.
      111. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
      112. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
      113. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
      114. Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
      115. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
      116. Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol 98(4):658-665, 2023. e-Pub 2023. PMID: 36683287.
      117. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
      118. Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer 129(4):580-589, 2023. e-Pub 2023. PMID: 36448227.
      119. Marx KR, Rausch CR, Lovell AR, Short NJ, Paul S, Jain N, Lee J, Savoy JM, Ravandi F, Jabbour E. Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals. Leuk Lymphoma 64(1):1-8, 2023. e-Pub 2023. PMID: 36222579.
      120. Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med 29(1):158-169, 2023. e-Pub 2023. PMID: 36624313.
      121. Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol 98(1):E11-E14, 2023. e-Pub 2023. PMID: 35633516.
      122. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
      123. Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 9(12):e878-e885, 2022. e-Pub 2022. PMID: 36279879.
      124. Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, Adimy Y, Geronimi J, Graham C, Jain N, Maus MV, Mohty M, Boissel N, Teshima T, Kato K, Benjamin R, Balandraud S. Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia. Cancer Res Commun 2(11):1520-1531, 2022. e-Pub 2022. PMID: 36970059.
      125. Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M, Group CS. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol 9(11):e833-e843, 2022. e-Pub 2022. PMID: 36228643.
      126. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
      127. Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
      128. Timofeeva N, Jain N, Irajizad E, Aslan B, Katayama H, Cai Y, Ayres M, Iles L, Vykoukal J, Dennison J, Hanash S, Wierda W, Gandhi V. CLL-532 Changes in Proteome of CLL (Chronic Lymphocytic Leukemia) Lymphocytes During Investigator-Initiated Trial of Ibrutinib Alone and in Combination With Venetoclax in Treatment-Naïve Patients With CLL. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S283, 2022. e-Pub 2022. PMID: 36163901.
      129. Rozovski U, Veletik I, Harris D, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Wierda W, Verstovsek S, Keating M, Estrov Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S271, 2022. e-Pub 2022. PMID: 36163878.
      130. Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short N, Daver N, Issa G, Jain N, Bull-Linderman D, DiNardo C, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia T. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
      131. Abuasab T, Alvarado Y, Issa G, Islam R, James N, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Pemmaraju N, Bravo GM, Pierce S, DiNardo C, Kadia T, Daver N, Konopleva M, Garcia-Manero G, Ravandi F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S237, 2022. e-Pub 2022. PMID: 36163813.
      132. Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S204, 2022. e-Pub 2022. PMID: 36163747.
      133. Baran N, Babakhanlou R, Sasaki K, Takahashi K, Short N, Ravandi F, Garcia-Manero G, Jabbour EJ, Kantarjian HM, Jain N. ALL-346 Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy: A Single-Center Experience With 9 Patients. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S201-S202, 2022. e-Pub 2022. PMID: 36163741.
      134. Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol 97(9):1135-1141, 2022. e-Pub 2022. PMID: 35713551.
      135. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
      136. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered CLL Treated with Firstline Bruton's Tyrosine Kinase Inhibitor-based Therapy: A Retrospective Analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
      137. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol:JCO2102823. e-Pub 2022. PMID: 35704787.
      138. Berkman AM, Andersen CR, Cuglievan B, McCall DC, Lupo PJ, Parsons SK, DiNardo CD, Short NJ, Jain N, Kadia TM, Livingston JA, Roth ME. Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiol Biomarkers Prev 31(6):OF1-OF9, 2022. e-Pub 2022. PMID: 35553621.
      139. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
      140. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
      141. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol. e-Pub 2022. PMID: 35595309.
      142. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol. e-Pub 2022. PMID: 35583199.
      143. Short NJ, Kantarjian HM, Ravandi F, Konopleva MY, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang SA, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver NG, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour EJ. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. e-Pub 2022. PMID: 35533262.
      144. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
      145. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1448, 2022. e-Pub 2022. PMID: 35411096.
      146. Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. e-Pub 2022. PMID: 35413152.
      147. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. e-Pub 2022. PMID: 35384048.
      148. Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma 63(4):885-893, 2022. e-Pub 2022. PMID: 35225133.
      149. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. e-Pub 2022. PMID: 35357036.
      150. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97(3):E100-E102, 2022. e-Pub 2022. PMID: 34989420.
      151. Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia. e-Pub 2022. PMID: 35132195.
      152. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2022. PMID: 34716921.
      153. Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver NG, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SR, Qazilbash MH, Konopleva MY, Kantarjian HM. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD. Blood Adv. e-Pub 2022. PMID: 35061885.
      154. Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol 145(5):529-536, 2022. e-Pub 2022. PMID: 35717939.
      155. Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol 12:833714, 2022. e-Pub 2022. PMID: 35273915.
      156. Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008312.
      157. Gaballa MR, Banerjee PP, Milton DR, Jiang X, Ganesh C, Khazal SJ, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta RS, Alatrash G, Khouri IF, Oran B, Marin D, Popat UR, Olson AL, Tewari P, Jain N, Jabbour EJ, Ravandi F, Kantarjian HM, Chen K, Champlin RE, Shpall EJ, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood. e-Pub 2021. PMID: 34914826.
      158. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare). Clin Cancer Res. e-Pub 2021. PMID: 34789482.
      159. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma:1-4. e-Pub 2021. PMID: 34668451.
      160. Brown PA, Shah B, Advani A, Aoun P, Boyer MW, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Jain N, Kirby S, Liedtke M, Litzow M, Logan A, Luger S, Maness LJ, Massaro S, Mattison RJ, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Rubnitz JE, Uy GL, Vusirikala M, Wieduwilt M, Lynn B, Berardi RA, Freedman-Cass DA, Campbell M. Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(9):1079-1109, 2021. e-Pub 2021. PMID: 34551384.
      161. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson PA, Kantarjian HM, Keating MJ, Burger JA. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. Blood. e-Pub 2021. PMID: 34521099.
      162. Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, Haddad FG, Jain N, Ravandi F, Short NJ, DiNardo CD, Takahashi K, Konopleva MY, Daver NG, Kadia TM, Garcia-Manero G, Garris R, O'Brien SM, Jabbour EJ. Outcomes of Acute Lymphoblastic Leukemia with KMT2A (MLL) rearrangement - The MD Anderson Experience. Blood Adv. e-Pub 2021. PMID: 34525185.
      163. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
      164. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
      165. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. e-Pub 2021. PMID: 34340254.
      166. Jain N. Evolving Treatment Paradigm in Frontline CLL. JCO Oncol Pract:OP2100486. e-Pub 2021. PMID: 34449250.
      167. Samra B, Khoury JD, Morita K, Ravandi F, Richard-Carpentier G, Short NJ, El Hussein S, Thompson PA, Jain N, Kantarjian HM, Jabbour EJ. Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. e-Pub 2021. PMID: 34464974.
      168. Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 96(7):E229-E232, 2021. e-Pub 2021. PMID: 33780038.
      169. Niswander LM, Loftus JP, É L, Caye-Eude A, Pondrom M, Hottman DA, Iacobucci I, Mullighan CG, Jain N, Konopleva M, Cavé H, Baruchel A, Rohrlich PS, Tasian SK. Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica. e-Pub 2021. PMID: 34196168.
      170. Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver NG, Pierce SR, Jabbour EJ, Kadia TM, DiNardo CD, Garcia-Manero G, Qazilbash MH, Konopleva MY, Kantarjian HM. Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood. e-Pub 2021. PMID: 34098573.
      171. Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. e-Pub 2021. PMID: 34138471.
      172. Jabbour E, Patel K, Jain N, Duose D, Luthra R, Short NJ, Zugmaier G, San Lucas A, Velasco K, Tran Q, Zaman F, Konopleva M, Kantarjian H. Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study. Am J Hematol. e-Pub 2021. PMID: 34161631.
      173. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. e-Pub 2021. PMID: 34110383.
      174. Jain N. How I manage chronic lymphocytic leukemia. Clin Adv Hematol Oncol 19(6):360-364, 2021. e-Pub 2021. PMID: 34106909.
      175. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol:JCO2003736. e-Pub 2021. PMID: 34043428.
      176. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. e-Pub 2021. PMID: 34007049.
      177. Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. e-Pub 2021. PMID: 33991360.
      178. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. e-Pub 2021. PMID: 33973230.
      179. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. e-Pub 2021. PMID: 33793964.
      180. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. e-Pub 2021. PMID: 33901324.
      181. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. e-Pub 2021. PMID: 33853292.
      182. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
      183. Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. e-Pub 2021. PMID: 33823073.
      184. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. e-Pub 2021. PMID: 33767403.
      185. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. e-Pub 2021. PMID: 33740268.
      186. Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, Kantarjian H. Acute lymphoblastic leukemia: A population- based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. e-Pub 2021. PMID: 33709456.
      187. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
      188. Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. e-Pub 2021. PMID: 33654205.
      189. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos J, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia. Blood. e-Pub 2021. PMID: 33786588.
      190. Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine. Am J Hematol. e-Pub 2021. PMID: 33639000.
      191. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
      192. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. e-Pub 2021. PMID: 33449377.
      193. Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W, Group U. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396(10266):1885-1894, 2020. e-Pub 2020. PMID: 33308471.
      194. Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, Wang L, Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
      195. Koller PB, Zhang H, Kantarjian H, Jabbour E, Pierce S, Gocho Y, Roberts KG, Yang W, Mullighan CG, Yang J, Konopleva M, Jain N. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis. Am J Hematol. e-Pub 2020. PMID: 33275800.
      196. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. e-Pub 2020. PMID: 33264443.
      197. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. e-Pub 2020. PMID: 33087831.
      198. Lyapichev KA, Sukswai N, Angelova E, Kersh MJ, Pierce S, Konopleva M, Jain N, Jabbour EJ, Jorgensen JL, Wang SA, Medeiros LJ, Khoury JD, Konoplev S. CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. Clin Lymphoma Myeloma Leuk. e-Pub 2020. PMID: 33129747.
      199. Gupta SK, Jain N, Tang G, Futreal A, Wang SA, Khoury JD, Yang RK, Fang H, Patel KP, Luthra R, Routbort M, Barkoh BA, Chen W, Mao X, Zhang J, Medeiros LJ, Bueso-Ramos CE, Loghavi S. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw 18(10):1300-1304, 2020. e-Pub 2020. PMID: 33022638.
      200. Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowdhury SM, Sircar A, Shirazi F, Singh RK, Alinari L, Zhu J, Havranek O, Tsichlis P, Woyach J, Baiocchi R, Samaniego F, Sehgal L. Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv 4(18):4382-4392, 2020. e-Pub 2020. PMID: 32926124.
      201. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv 4(18):4508-4511, 2020. e-Pub 2020. PMID: 32946567.
      202. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma:1-5. e-Pub 2020. PMID: 32955970.
      203. Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res 98:106445. e-Pub 2020. PMID: 32937250.
      204. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. e-Pub 2020. PMID: 32896301.
      205. John TM, Malek AE, Mulanovich VE, Adachi JA, Raad II, Hamilton AR, Shpall EJ, Rezvani K, Aitken SL, Jain N, Klein K, Martinez F, Jacob CN, Cherian SV, Manzano JM, Muthu M, Wegner R. Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids. Mayo Clin Proc 95(9):2038-2040, 2020. e-Pub 2020. PMID: 32861345.
      206. Alotaibi AS, Abdulrazzaq M, Patel KP, Ravandi F, Konoplev S, Bueso-Ramos C, Yin CC, Muzzafar T, Tang G, Futreal A, Jain N, Konopleva MY, Pemmaraju N. Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leuk Lymphoma:1-3. e-Pub 2020. PMID: 32657180.
      207. Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol. e-Pub 2020. PMID: 32686139.
      208. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
      209. Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma:1-3. e-Pub 2020. PMID: 32654562.
      210. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
      211. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma:1-4. e-Pub 2020. PMID: 32530347.
      212. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. e-Pub 2020. PMID: 32546726.
      213. Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. e-Pub 2020. PMID: 32501545.
      214. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. e-Pub 2020. PMID: 32499238.
      215. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2020. PMID: 32035785.
      216. Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov 10(3):440-459, 2020. e-Pub 2020. PMID: 31915197.
      217. Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv 4(4):599-606, 2020. e-Pub 2020. PMID: 32074275.
      218. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive Factors. Blood 135(7):510-513, 2020. e-Pub 2020. PMID: 31895947.
      219. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
      220. Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv 4(3):449-457, 2020. e-Pub 2020. PMID: 32012214.
      221. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. e-Pub 2020. PMID: 32099037.
      222. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma 61(2):1-5, 2020. e-Pub 2020. PMID: 31566032.
      223. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2020. PMID: 31553487.
      224. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. e-Pub 2019. PMID: 31862959.
      225. Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol 94(12):1388-1395, 2019. e-Pub 2019. PMID: 31595534.
      226. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
      227. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. e-Pub 2019. PMID: 31724006.
      228. Jain N, O'Brien S. The Shifting Paradigm in Chronic Lymphocytic Leukemia: Is Chemotherapy Still Relevant?. Cancer J 25(6):374-377, 2019. e-Pub 2019. PMID: 31764117.
      229. Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma 60(11):1-3, 2019. e-Pub 2019. PMID: 31012358.
      230. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL. Blood 134(22):1951-1959, 2019. e-Pub 2019. PMID: 31537528.
      231. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
      232. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
      233. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther 12(3):161-165, 2019. e-Pub 2019. PMID: 28830803.
      234. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, Borthakur G, Jabbour E, Kadia T, Daver N, DiNardo CD, Jain N, Konopleva M, Cortes J, Ravandi F, Yilmaz M. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer 125(18):3219-3224, 2019. e-Pub 2019. PMID: 31150121.
      235. Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA. B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. Gynecol Oncol Rep 29:94-97, 2019. e-Pub 2019. PMID: 31467959.
      236. Jain N, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med 381(8):789, 2019. e-Pub 2019. PMID: 31433937.
      237. Khogeer H, Rahman H, Jain N, Angelova EA, Yang H, Quesada A, Ok CY, Sui D, Wei P, Al Fattani A, Pierce S, Loghavi S, Lamb A, Hu P, Thakral B, Kanagal-Shamanna R, Jorgensen JL, Jabbour EJ, Kantarjian HM, Medeiros LJ, Khoury JD. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol 186(4):538-548, 2019. e-Pub 2019. PMID: 31115909.
      238. Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
      239. Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk 19(7):431-440.e13, 2019. e-Pub 2019. PMID: 31056348.
      240. Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, Wang L, Hu J, Jing H, Chen Z, Jain N, Duy C, Mistry SJ, Cerchietti L, Cross JR, Cantley LC, Green MR, Lin H, Melnick AM. Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer Cell 35(6):916-931.e9, 2019. e-Pub 2019. PMID: 31185214.
      241. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
      242. Jain N. Optimizing drug dosing for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol 17(6):330-331, 2019. e-Pub 2019. PMID: 31437134.
      243. Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo TH. Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther 12(2):115-118, 2019. e-Pub 2019. PMID: 29409729.
      244. Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett WK. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
      245. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. e-Pub 2019. PMID: 31076409.
      246. Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, Cassaday RD, Litzow M, Advani A, Aoun P, Bhatnagar B, Boyer MW, Bryan T, Burke PW, Coccia PF, Coutre SE, Jain N, Kirby S, Liu A, Massaro S, Mattison RJ, Oluwole O, Papadantonakis N, Park J, Rubnitz JE, Uy GL, Gregory KM, Ogba N, Shah B. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. J Natl Compr Canc Netw 17(5):414-423, 2019. e-Pub 2019. PMID: 31085755.
      247. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
      248. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2019. PMID: 30406944.
      249. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
      250. Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
      251. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. e-Pub 2018. PMID: 30508305.
      252. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. e-Pub 2018. PMID: 30530801.
      253. Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. e-Pub 2018. PMID: 30501869.
      254. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
      255. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. e-Pub 2018. PMID: 30467242.
      256. Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044-4055, 2018. e-Pub 2018. PMID: 30307611.
      257. Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev S. High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol. e-Pub 2018. PMID: 30181564.
      258. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 9(72):33710-33718, 2018. e-Pub 2018. PMID: 30263097.
      259. O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study. Am J Hematol. e-Pub 2018. PMID: 30094870.
      260. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. e-Pub 2018. PMID: 30153704.
      261. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
      262. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
      263. Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124(13):2758-2765, 2018. e-Pub 2018. PMID: 29660836.
      264. Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain N, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer 124(12):2534-2540, 2018. e-Pub 2018. PMID: 29645075.
      265. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32(4):960-970, 2018. e-Pub 2018. PMID: 28972595.
      266. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9(30):21268-21280, 2018. e-Pub 2018. PMID: 29765537.
      267. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. e-Pub 2018. PMID: 29769624.
      268. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
      269. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2018. PMID: 29178361.
      270. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93(3):401-407, 2018. e-Pub 2018. PMID: 29218851.
      271. Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, Singh RK, Berkova Z, Wise JF, Braun FK, Wang X, Patel K, Xu-Monette ZY, Courty J, Young KH, Sehgal L, Samaniego F. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia 32(3):663-674, 2018. e-Pub 2018. PMID: 28690315.
      272. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma:1-6. e-Pub 2018. PMID: 29465264.
      273. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. e-Pub 2018. PMID: 29479067.
      274. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. e-Pub 2018. PMID: 29434334.
      275. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
      276. Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood 131(8):877-887, 2018. e-Pub 2018. PMID: 29191916.
      277. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu SC, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Levine R, Tasian SK, Mullighan CG, Weinstock DM, Fruman DA, Konopleva M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade inCRLF2rearranged and/orJAKdriven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget 9(8):8027-8041, 2018. e-Pub 2018. PMID: 29487712.
      278. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2018. PMID: 29164608.
      279. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
      280. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology 7(4):e1417720, 2018. e-Pub 2018. PMID: 29632735.
      281. Boddu P, Shah AR, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jain N, Alhuraiji A, Burger J, Kornblau S, Pierce S, Dellasala S, Jabbour E, Kantarjian H, Cortes J. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma:1-11. e-Pub 2017. PMID: 28972430.
      282. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens. Am J Hematol 92(10):E595-E597, 2017. e-Pub 2017. PMID: 28646517.
      283. Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. Am J Hematol. e-Pub 2017. PMID: 28850699.
      284. Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2017. PMID: 28927784.
      285. Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. e-Pub 2017. PMID: 28860345.
      286. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. e-Pub 2017. PMID: 28859185.
      287. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123(16):3050-3060, 2017. e-Pub 2017. PMID: 28387922.
      288. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. e-Pub 2017. PMID: 28708931.
      289. Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol 92(7):660-667, 2017. e-Pub 2017. PMID: 28370201.
      290. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. e-Pub 2017. PMID: 28722170.
      291. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma:1-8. e-Pub 2017. PMID: 28718728.
      292. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268-2273, 2017. e-Pub 2017. PMID: 28171709.
      293. Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. e-Pub 2017. PMID: 28663582.
      294. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian H, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. e-Pub 2017. PMID: 28608976.
      295. Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda WG. PET-positive lymphadenopathy in CLL-Not always Richter transformation. Am J Hematol 92(4):405-406, 2017. e-Pub 2017. PMID: 27677095.
      296. Konoplev S, Lu X, Konopleva M, Jain N, Ouyang J, Goswami M, Roberts KG, Valentine M, Mullighan CG, Bueso-Ramos C, Zweidler-McKay PA, Jorgensen JL, Wang SA. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience. Am J Clin Pathol 147(4):357-363, 2017. e-Pub 2017. PMID: 28340183.
      297. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Shamanna RK, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. e-Pub 2017. PMID: 28379307.
      298. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol 92(3):279-285, 2017. e-Pub 2017. PMID: 28052371.
      299. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
      300. Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2017. PMID: 27696391.
      301. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, Zweidler-McKay P, Lu X, Fawcett G, Wang SA, Konoplev S, Harvey RC, Chen IM, Payne-Turner D, Valentine M, Thomas D, Garcia-Manero G, Ravandi F, Cortes J, Kornblau S, O'Brien S, Pierce S, Jorgensen J, Shaw KR, Willman CL, Mullighan CG, Kantarjian H, Konopleva M. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood 129(5):572-581, 2017. e-Pub 2017. PMID: 27919910.
      302. Mathur R, Sehgal L, Havranek O, Kohrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica 102(2):373-380, 2017. e-Pub 2017. PMID: 27742770.
      303. Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2017. PMID: 27795561.
      304. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol 198(4):1740-1747, 2017. e-Pub 2017. PMID: 28077600.
      305. Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya-Matsuoka C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol 92(2):155-160, 2017. e-Pub 2017. PMID: 27874212.
      306. Khan M, Paul S, Farooq S, Oo TH, Ramshesh P, Jain N. Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6-Phosphate Dehydrogenase Deficiency. Curr Drug Saf. e-Pub 2017. PMID: 28078984.
      307. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol 35(2):JCO2016682856, 2017. e-Pub 2017. PMID: 27870563.
      308. Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2017. PMID: 27602508.
      309. Boddu P, Yin CC, Kanagal-Shamanna R, Tang G, Thakral B, Kadia T, Konopleva M, Jabbour E, Jain N. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Rep Hematol 2017:2413587, 2017. e-Pub 2017. PMID: 29075538.
      310. Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Yin CC, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver N, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. e-Pub 2016. PMID: 28006851.
      311. Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. e-Pub 2016. PMID: 28017967.
      312. Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
      313. Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
      314. Abaza Y, Kantarjian HM, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. e-Pub 2016. PMID: 28003274.
      315. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. e-Pub 2016. PMID: 27655665.
      316. Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda W. PET-positive lymphadenopathy in CLL - Not always Richter transformation. American Journal of Hematology, 2016. e-Pub 2016.
      317. Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
      318. Short NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, Faderl S, Burger JA, Garris R, Qiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol 91(4):385-9, 2016. e-Pub 2016. PMID: 26800008.
      319. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 101(6):e254-8, 2016. e-Pub 2016. PMID: 27013651.
      320. Alhuraiji A, Jain N. Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther. e-Pub 2016. PMID: 27362439.
      321. Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther. e-Pub 2016. PMID: 27352257.
      322. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127(15):1863-9, 2016. e-Pub 2016. PMID: 26747249.
      323. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122(4):565-73, 2016. e-Pub 2016. PMID: 26588193.
      324. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392-400, 2016. e-Pub 2016. PMID: 26492205.
      325. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.
      326. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121(20):3612-21, 2015. e-Pub 2015. PMID: 26193999.
      327. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res 13(5):944-53, 2015. e-Pub 2015. PMID: 25733697.
      328. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125(13):2062-7, 2015. e-Pub 2015. PMID: 25573991.
      329. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2015. PMID: 25107338.
      330. Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE. Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw 13(1):19-22, 2015. e-Pub 2015. PMID: 25583766.
      331. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
      332. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 2014. e-Pub 2014. PMID: 24778152.
      333. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic leukemia. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
      334. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET findings, histological features, clinical characteristics and survival in 332 patients with chronic lymphocytic leukemia. Blood 123(18):2783-90, 2014. e-Pub 2014. PMID: 24615780.
      335. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
      336. Pemmaraju N, Shetty AV, Prieto VG, Jain N, Kontoyiannis DP, Borthakur G. Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum, and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol. e-Pub 2014. PMID: 24592915.
      337. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 20(2):490-8, 2014. e-Pub 2014. PMID: 24178622.
      338. Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055-61, 2013. e-Pub 2013. PMID: 23940084.
      339. Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib Therapy in a Patient with Suspected Chronic Neutrophilic Leukemia and FIP1L1-PDGFRA Rearrangement. Blood 122(19):3387-8, 2013. e-Pub 2013. PMID: 24203930.
      340. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune Reconstitution after Combined Haploidentical and Umbilical Cord Blood Transplantation. Leuk Lymphoma 54(6):1242-9, 2013. e-Pub 2013. PMID: 23088744.
      341. Hossain N, Jain N, Steinmetz J, McConville J, Anastasi J, Odenike O. A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement. Chest 142(6):1680-3, 2012. e-Pub 2012. PMID: 23208343.
      342. Garcia JS, Jain N, Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther 3:1-13, 2010. e-Pub 2010. PMID: 20616953.
      343. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115(6):1131-6, 2010. e-Pub 2010. PMID: 20008298.
      344. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115(19):4533-9, 2009. e-Pub 2009. PMID: 19637351.
      345. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 115(17):3924-34, 2009. e-Pub 2009. PMID: 19536894.
      346. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115(14):3217-21, 2009. e-Pub 2009. PMID: 19441109.
      347. Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 33(6):837-9, 2009. e-Pub 2009. PMID: 19013640.
      348. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-63, 2009. e-Pub 2009. PMID: 19282457.
      349. Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia: report of three patients and review of literature. Clinical Leukemia 2(1):64-67, 2008. e-Pub 2008.
      350. Jain N, Kantarjian H, Ault P, Cortes J. Scrotal edema associated with the use of dasatinib in patients with chronic myeloid leukemia. Clinical Leukemia 1(6):357-58, 2007. e-Pub 2007.
      351. Jain N, Fisk D, Sotir M, Kehl KS. West Nile encephalitis, status epilepticus and West Nile pneumonia in a renal transplant patient. Transplant International 20(9):800-3, 2007. e-Pub 2007. PMID: 17630998.
      352. Jain N, Patel D, Pfeifer KJ. An unusual case of vertebral osteomyelitis in a young healthy adult. Wisconsin Medical Journal 106(3):152-54, 2007. e-Pub 2007. PMID: 17642354.

      Invited Articles

      1. Strati P, Jain N, O'Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc 93(5):651-664, 2018. e-Pub 2018. PMID: 29728204.
      2. Boddu P, Jain N. Update on signal inhibitors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 16(4):279-288, 2018. e-Pub 2018. PMID: 29742083.
      3. Jain N. Examining the Safety of CLL Medication. CURE Today, 2017. e-Pub 2017.
      4. Wells J, Jain N, Konopleva M. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. Clin Adv Hematol Oncol 15(7):554-561, 2017. e-Pub 2017. PMID: 28749919.
      5. Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs 26(5):625-632, 2017. e-Pub 2017. PMID: 28388280.
      6. Jain N, O'Brien S. First-line therapy for young patients with CLL. Hematology Am Soc Hematol Educ Program 2016(1):146-148, 2016. e-Pub 2016. PMID: 27913473.
      7. Agbay RL, Jain N, Loghavi S, Medeiros LJ, Khoury JD. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 91(10):1036-43, 2016. e-Pub 2016. PMID: 27414262.
      8. Jain N, Keating MJ. Richter transformation of CLL. Expert Rev Hematol 9(8):793-801, 2016. e-Pub 2016. PMID: 27351634.
      9. Jain N, O'Brien S. Targeted therapies for CLL: Practical issues with the changing treatment paradigm. Blood Rev 30(3):233-44, 2016. e-Pub 2016. PMID: 26776345.
      10. George B, Kantarjian H, Jabbour E, Jain N. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia. Immunotherapy 8(2):135-43, 2016. e-Pub 2016. PMID: 26780449.
      11. Jain N, O'Brien S. Initial treatment of CLL: integrating biology and functional status. Blood 126(4):463-70, 2015. e-Pub 2015. PMID: 26065656.
      12. Jain N. New developments in Richter syndrome. Clin Adv Hematol Oncol 13(4):220-2, 2015. e-Pub 2015. PMID: 26352579.
      13. Jain N, O'Brien S, Thomas D, Kantarjian H. Inotuzumab Ozogamicin in the treatment of acute lymphoblastic leukemia. Front Biosci (Elite Ed) 6:40-5, 2014. e-Pub 2014. PMID: 24389139.
      14. Jain N, O'Brien S. The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment. Expert Rev Hematol 6(5):575-86, 2013. e-Pub 2013. PMID: 24083594.
      15. Jain N, O'Brien S. Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am 27(4):851-60, 2013. e-Pub 2013. PMID: 23915749.
      16. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications. Biol Blood Marrow Transplant 19(5):682-91, 2013. e-Pub 2013. PMID: 23142329.
      17. Jain N, O'Brien S. Chronic lymphocytic leukemia with deletion 17p: emerging treatment options. Oncology (Williston Park) 11(11):1067-70, 2012. e-Pub 2012. PMID: 23330347.
      18. Jain N, van Besien K. Chronic Myelogenous Leukemia. Elsevier's First Consult online, 2012. e-Pub 2012.
      19. Quintás-Cardama A, Jain N, Verstovsek S. Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117(24):5439-49, 2011. e-Pub 2011. PMID: 21692073.
      20. Jain N, van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am 25(5):1025-48, vi, 2011. e-Pub 2011. PMID: 22054733.
      21. Jain N, Odenike O. The Emerging Role of the Histone deactylase inhibitor Romidepsin in Hematologic Malignancies. Expert Opinion on Pharmacotherapy 11(18):3073-84, 2010. e-Pub 2010.
      22. Jain N, Lamanna N. Incorporating Prognostic Information into Treatment Decisions in CLL. Current Oncology Reports 11(5):353-9, 2009. e-Pub 2009.
      23. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. The International Journal of Biochemistry and Cell Biology 41(1):72-80, 2009. e-Pub 2009.
      24. Jain N, Verstovsek S. Systemic Mastocytosis. Drugs of the Future 33(2):187-92, 2008. e-Pub 2008.

      Review Articles

      1. Kantarjian, HM, Chifotides, H, Haddad, FG, Jabbour, EJ, Jain, N, Kadia, TM, Ravandi-Kashani, F, Welch, MA, Wierda, WG, Freireich, EJ. The Care and Cure of the Leukemias in 2026. American journal of hematology 101(4):807-831, 2026. e-Pub 2026. PMID: 41761287.
      2. Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Garcia-Manero, G, Issa, GC, Jabbour, EJ, Jain, N, Kadia, TM, Loghavi, S, Ravandi-Kashani, F, Tang, G, Welch, MA, Wierda, WG. A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens. Cancer 131(21), 2025. e-Pub 2025. PMID: 41129068.
      3. Haddad, FG, Kantarjian, HM, Senapati, J, Jain, N, Short, NJ, Jabbour, EJ. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant. Clinical Lymphoma, Myeloma and Leukemia 25(10):711-719, 2025. e-Pub 2025. PMID: 40683769.
      4. Haddad, FG, Kantarjian, HM, Short, NJ, Jain, N, Senapati, J, Ravandi-Kashani, F, Jabbour, EJ. Incorporation of Immunotherapy Into Adult B-Cell Acute Lymphoblastic Leukemia Therapy. JNCCN Journal of the National Comprehensive Cancer Network 23(8), 2025. e-Pub 2025. PMID: 40659041.
      5. Senapati J, Kantarjian H, Habib D, Haddad FG, Jain N, Short NJ, Jabbour E. Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy. Leuk Lymphoma 66(6):989-1000, 2025. e-Pub 2025. PMID: 39791458.
      6. Kantarjian, HM, Jain, N, Litzow, M, Luger, SM, Papayannidis, C, Ribera, JM, Short, NJ, Chifotides, H, Jabbour, EJ. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer 131(10), 2025. e-Pub 2025. PMID: 40323723.
      7. Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, Kadia, TM, Guest, E, Short, NJ, McCall, DC, Daver, N, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
      8. Timofeeva, N, Jain, N, Gandhi, VV. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia. Blood Neoplasia 1(3), 2024. e-Pub 2024. PMID: 39949788.
      9. Jain, N, Wierda, WG, O’Brien, S. Chronic lymphocytic leukaemia. The Lancet 404(10453):694-706, 2024. e-Pub 2024. PMID: 39068951.
      10. Short NJ, Jabbour E, Jain N, Kantarjian H. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions. J Hematol Oncol 17(1):32, 2024. e-Pub 2024. PMID: 38734670.
      11. Haddad FG, Jabbour E, Short NJ, Jain N, Kantarjian H. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(5):271-276, 2024. e-Pub 2024. PMID: 38185587.
      12. Senapati J, Kantarjian H, Haddad FG, Short NJ, Welch MA, Jain N, Jabbour E. SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 2024. PMID: 38195323.
      13. Strati, P, Gregory, T, Majhail, NS, Jain, N. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies. JCO Oncology Practice 19(9):706-713, 2023. e-Pub 2023. PMID: 37406255.
      14. Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol 16(1):22, 2023. e-Pub 2023. PMID: 36927623.
      15. Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ. The cure of leukemia through the optimist's prism. Cancer. e-Pub 2021. PMID: 34614211.
      16. Cherng HJ, |Jain N. First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?. Hematol Oncol Clin North Am 35(4):725-738, 2021. e-Pub 2021. PMID: 34174983.
      17. Thakral B, Jain N, Tang G, Konoplev S, Vega F, Medeiros LJ, Wang SA. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. Ann Diagn Pathol 53:151767. e-Pub 2021. PMID: 34118580.
      18. George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, Mamgain M, Singhal NK, Sehgal L, Jain N. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. Cancers (Basel) 12(5), 2020. e-Pub 2020. PMID: 32455989.
      19. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol:1-13. e-Pub 2020. PMID: 32392559.
      20. Jain N. Selecting Frontline Therapy for CLL in 2018. Hematology Am Soc Hematol Educ Program 2018(1):242-247, 2018. e-Pub 2018. PMID: 30504317.
      21. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. e-Pub 2017. PMID: 28925994.
      22. Jain N, Odenike O. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. Expert Opin Pharmacother 11(18):3073-84, 2010. e-Pub 2010. PMID: 21080855.
      23. Jain N, Lamanna N. Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia. Curr Oncol Rep 11(5):353-9, 2009. e-Pub 2009. PMID: 19679010.
      24. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol 41(1):72-80, 2009. e-Pub 2009. PMID: 18948224.
      25. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 49(7):1399-402, 2008. e-Pub 2008. PMID: 18452066.

      Other Articles

      1. DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 40(1):262, 2026. PMID: 41372600.
      2. Shadman, M, Fakhri, B, Jain, N Consensus in CLL. Blood Advances 9(5):1210-1212, 2025. PMID: 40067336.
      3. Jain, N Doublet vs Triplet Combinations for Frontline Treatment of Chronic Lymphocytic Leukemia. Clinical Advances in Hematology and Oncology 22(8):364-366, 2024. PMID: 39356813.

      Editorials

      1. Jain, N, Ferrajoli, A, O'Brien, S, Wierda, WG. Is CLL curable?. HemaSphere 10(2), 2026. PMID: 41743268.
      2. Jain, N, Jabbour, EJ, Konopleva, M. BCL2 inhibition in adult acute lymphoblastic leukemia. Haematologica 110(5):1053-1054, 2025. PMID: 39945010.
      3. Jain N, O'Brien S. BCR inhibitor failure in CLL: an unmet need. Blood 128(18):2193-2194, 2016. PMID: 27811187.
      4. Jain N, Steensma D, Stewart DJ, Kantarjian H. Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era. J Oncol Pract 12(4):283-5, 2016. PMID: 26907450.
      5. Jain N, Kantarjian H. Insurers play to win, but the patients lose. Houston Chronicle, 2015.

      Book Chapters

      1. Afrough, A, Im, JS, Jain, N, Kebriaei, P. Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia, 233-245, 2023.
      2. Jain N, Bueso-Ramos C, O'Brien S, Wierda WG. Chronic Lymphocytic Leukemia and Associated Disorders. In: MD Anderson Manual of Medical Oncology. 3rd Edition. McGraw-Hill, 2016.
      3. Jain N, Faderl S, Kantarjian H, O'Brien S. Acute Lymphoblastic Leukemia. In: Holland-Frei Cancer Medicine. 9th Edition, 2016.
      4. Jain N, O'Brien S, Ravandi-Kashani F. Targeted Therapy for Acute Lymphoblastic Leukemia. In: Targeted Therapy in Translational Cancer Research (Translational Oncology). 1st Edition. Wiley-Blackwell, 2015.
      5. Jain N, Gurbuxani S, Rhee C, Stock W. Acute Lymphocytic Leukemia in Adults. In: Hematology: Basic Principles and Practice (Hoffman's). 6th Edition. Churchill Livingstone, 2012.
      6. Jain N, Verstovsek S. Philadelphia-chromosome negative myeloproliferative disorders. In: The MD Anderson Manual of Medical Oncology. 2nd Edition. McGraw-Hill Professional, 2011.

      Letters to the Editor

      1. Arora S, Kantarjian H, Sasaki K, Jain N, Li Z, Qiao W, Loghavi S, Tang G, Rausch C, Ravandi F, Haddad FG, Senapati J, Bravo GM, Bazinet A, Khouri R, Garris R, Garcia-Manero G, Short NJ, Jabbour E. Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL. Am J Hematol 101: 2038-2043, 2026.
      2. Jabbour E, Goulart H, Sasaki K, Rausch CR, Jain N, Kadia TM, DiNardo C, Daver N, Pemmaraju N, Ravandi F, Montalban-Bravo G, Garcia-Manero G, Hammond D, Swaminathan M, Hachem M, Khouri R, Ohanian M, Garris R, Short NJ, Kantarjian HM. Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis. Am J Hematol 101: 1729-1736, 2026.
      3. Sasaki K, Kantarjian H, Rausch CR, Goulart H, Jain N, Huang X, Hachem M, Wierda WG, Kadia TM, Borthakur G, Issa GC, Alvarado Y, Pemmaraju N, Garris R, Ravandi F, Garcia-Manero G, Short NJ, Jabbour E. Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Am J Hematol 101: 1717-1722, 2026.
      4. Tantawy, S, Aslan, B, Manyam, GC, Iles, LR, Timofeeva, N, Singh, N, Jain, N, Ferrajoli, A, Thompson, PA, Patel, KP, Desikan, SP, Wierda, WG, Gandhi, VV. Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression. Blood cancer journal 15, 2025.
      5. Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.
      6. Goulart, H, Jabbour, EJ, Short, NJ, Jain, N, Issa, GC, Atluri, H, Bataller Torralba, A, Kadia, TM, Daver, N, DiNardo, C, Garris, R, Senapati, J, Ravandi-Kashani, F, Kantarjian, HM. Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens. American journal of hematology 100: 2128-2133, 2025.
      7. Zhou, T, Short, NJ, Jain, N, Patel, KP, Jabbour, EJ, Kantarjian, HM, Medeiros, LJ, Iorgulescu, JB. Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL). Leukemia 39: 1769-1772, 2025.
      8. Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
      9. Rafaeli N, Costa DM, Ledesma C, Jain N, Tewari P, Khouri I, Alatrash G, Short N, Jabbour E, Rezvani K, Alousi A, Popat U, Champlin R, Shpall E, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 25: e374-e377, 2025.
      10. Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
      11. Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
      12. Senapati, J, Jabbour, EJ, Short, NJ, Jain, N, Haddad, FG, Bathala, TK, Kovalenko, I, Bidikian, A, Ravandi-Kashani, F, Khouri, IF, Kadia, TM, Garris, R, Montalban Bravo, G, Chien, KS, Shpall, E, Kebriaei, P, Kantarjian, HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood cancer journal 14, 2024.
      13. Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
      14. Chen Q, Jain N, Flowers CR, Chhatwal J. Reply to C. Nabhan et al. J Clin Oncol 35: 1864-1865, 2017.
      Read More
      Less

      Patient Reviews


      CV information above last modified November 05, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Leukemia

      • Leukemia Center

      • Leukemia Department

      • Cancer Medicine Division

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top